Correction to article DOI: https://dx.doi.org/10.18632/oncotarget.2367

Alifrangis, C

Carter, P

Cereser, B

Chandrasinghe, P

Del Bel Belluz, L

Fotopoulou, C

Frilling, A

Herzog, T

Krell, J

Moderau, N

Stebbing, J

Tabassum, N

Oncotarget

English

Carter, Philip

Alifrangis, Costi

Cereser, Biancastella

Chandrasinghe, Pramodh

Del Bel Belluz, Lisa

Fotopoulou, Christina

Frilling, Andreja

Herzog, Thomas

Moderau, Nina

Tabassum, Neha

Krell, Jonathan

Stebbing, Justin

Spiral - Imperial College Digital Repository

Oncotarget15164www.oncotarget.comwww.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 19), pp: 15164-15164Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancyPhilip Carter1, Costi Alifrangis2, Biancastella Cereser1, Pramodh Chandrasinghe1,3, Lisa Del Bel Belluz1, Christina Fotopoulou1, Andreja Frilling1, Thomas Herzog4,5, Nina Moderau1, Neha Tabassum1, Jonathan Krell1 and Justin Stebbing11 Department of Surgery and Cancer, Imperial College, London, UK2 Department of Oncology, University College Hospital, London, UK3 Department of Surgery, University of Kelaniya, Kelaniya, Sri Lanka4 Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, USA5 University of Cincinnati Cancer Institute, University of Cincinnati, Cincinnati, USAPublished: March 13, 2018Copyright: Carter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This article has been corrected: The proper Materials and Methods and Conflicts of Interest information is as follows:MATERIALS AND METHODSThe Caris CODE database (Comprehensive Oncology Database Explorer) version 1.0 contains tumor molecular profile data for 841 patients with solid tumors. It contains demographic information about these patients, the drug treatments that they received before and after molecular profiling and their clinical outcomes. There are 112 advanced stage female genital tract cancer patients described within this resource, and we mined this cohort after web scraping the data, to assess how much tumor profiling recommendations were used in drug selection by clinicians, and if any molecular subsets had different outcomes. Tables 1 and 2 describe the clinical and demographic characteristics of the female genital tract cohort that was studied here.The amount of time that patients were monitored varied, as shown in Figure 3; on average patients’ treatment records were available for 921 days after diagnosis (938 for matched treatment patients, 897 for unmatched), and on average the time of monitoring after profiling was 531 days. The longest amount of time that treatment records were available, i.e. before and after profiling up until the last day of contact, was 4871 days. The longest time of monitoring after profiling (the patient represented on the furthest right of Figure 1) was 1366 days which was 1440 days after diagnosis.The data were analysed independently of Caris. Patients were covered under 1 of 4 different protocols or exemptions, listed as follows. (1). The Caris Registry Protocol (TCREG-001-00-V2-1209) was approved by WIRB (WIRB Tracking #20092285) and has an NCT# of NCT02678754. (2). The Caris POA Prospective Repository (COE-001-0815) was approved by WIRB (WIRB Tracking #20162864) and has an NCT# of NCT03324841. (3). The Caris POA Retrospective Repository (COE-002-0116) was approved by WIRB (WIRB Tracking #20162657) and has an NCT# of NCT 00326499. (4). ION data is covered under an IRB exemption. All data are retrospective and have been de-identified prior to Caris receiving it and authors performing independent analyses.CONFLICTS OF INTERESTAuthors received no funding or honoraria for this publication. The data were analysed independently of Caris. Thomas Herzog is on the scientific advisory board of Caris Life Sciences.Original article: Oncotarget. 2018; 9:6007-6014. https://doi.org/10.18632/oncotarget.23675 Correction

Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy

Philip Carter

Costi Alifrangis

Biancastella Cereser

Pramodh Chandrasinghe

Lisa Del Bel Belluz

Christina Fotopoulou

Andreja Frilling

Thomas Herzog

Nina Moderau

Neha Tabassum

Jonathan Krell

Justin Stebbing

Crossref

Tumor molecular profiling has enabled selection of targeted therapies in a host of solid tumors. Here we used a retrospective clinical cohort, to evaluate the benefit of tailoring treatments for female genital tract malignancy, using tumor molecular profiles. Clinical outcome data for 112 patients was retrospectively separated into two groups. These either followed a matched treatment plan that incorporated at least one drug recommended according to their tumor profile and none that were expected to have no benefit (64 patients), or was unmatched with suggested treatments and received at least one drug that was anticipated to lack benefit for that tumor (48 patients).

In the group of patients whose drugs matched those recommended by molecular profiling of their tumor, their overall survival was 593 days on average, compared to 449 days for patients that did not; removing drugs predicted to have no benefit from treatment regimens received after profiling increased survival by 144 days on average (P = 0.0265). In the matched treatment group, 30% of patients had died by the last time of monitoring, whereas this was 40% in the unmatched group (P = 0.2778). The IHC biomarker for the progesterone receptor was demonstrated to be prognostic for survival

Carter, philip

Alifrangis, costi

Chandrasinghe, pramodh

Del Bel Belluz, lisa

Fotopoulou, christina

Frilling, andrea

Herzog, thomas

Moderau, nina

Tabassum, neha

Krell, jonathan

Stebbing, justin

Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy

http://spiral.imperial.ac.uk/bitstream/10044/1/59665/2/Correction%3a%20Assessing%20tumor%20molecular%20profiling%20to%20guide%20treatments%20for%20patients%20with%20advanced%20female%20genital%20tract%20malignancy.pdf

Correction: Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy

Abstract

Similar works

Full text

Available Versions

Spiral - Imperial College Digital Repository

Crossref

Spiral - Imperial College Digital Repository

Crossref